MRTX849 for Colorectal Cancer

Phase-Based Estimates
2
Effectiveness
3
Safety
Research Site, New Brunswick, NJ
Colorectal Cancer+2 More
MRTX849 - Drug
Eligibility
18+
All Sexes
Eligible conditions
Colorectal Cancer

Study Summary

This study is evaluating whether a drug may help treat colorectal cancer.

See full description

Eligible Conditions

  • Colorectal Cancer
  • Colorectal Neoplasms
  • Advanced Colorectal Cancer
  • Metastatic Colorectal Cancer (CRC)

Treatment Effectiveness

Effectiveness Estimate

2 of 3
This is better than 85% of similar trials

Study Objectives

This trial is evaluating whether MRTX849 will improve 2 primary outcomes and 5 secondary outcomes in patients with Colorectal Cancer. Measurement will happen over the course of 30 months.

30 months
Adverse Events
Duration of Response (DOR)
Objective Response Rate (ORR)
Overall Survival (OS)
Patient Reported Outcomes (PROs)
Progression-free Survival (PFS)
Quality of Life Assessment

Trial Safety

Safety Estimate

3 of 3
This is better than 85% of similar trials

Trial Design

2 Treatment Groups

mFOLFOX6 or FOLFIRI
MRTX849 + Cetuximab

This trial requires 420 total participants across 2 different treatment groups

This trial involves 2 different treatments. MRTX849 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.

MRTX849 + Cetuximab
mFOLFOX6 or FOLFIRI
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cetuximab
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 30 months
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 30 months for reporting.

Closest Location

Research Site - New Brunswick, NJ

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
This text is discussing a colorectal carcinoma that has a KRAS G12C mutation. show original
People who have advanced cancer that was first treated with a chemotherapy regimen including either oxaliplatin or irinotecan, and who then had a documented progression of their disease, may be eligible to receive treatment with Ramucirumab. show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can colorectal cancer be cured?

Add answer

There is no evidence that colorectal cancer can be completely cured. However, with good management, most colorectal cancer patients can do well and live a normal lifespan.

Unverified Answer

What causes colorectal cancer?

Add answer

Colorectal cancer is a curable disease, especially when diagnosed early--as many as 50 percent of colorectal cancer patients have no symptoms. A colorectal cancer screening program would reduce colorectal cancer mortality from its present level of 30% to approximately 20 percent.

Unverified Answer

How many people get colorectal cancer a year in the United States?

Add answer

It has not been determined whether cancer in the colon or stomach is associated with the development or worsening of depression. The study has not determined whether specific cancer screening practices or medical treatments influence an increased probability for individuals with certain medical conditions, such as those of the lung, to develop or exacerbate a major depressive episode. This question requires further clarification.

Unverified Answer

What are the signs of colorectal cancer?

Add answer

Symptoms of CRC include unexplained abdominal or rectal pain, bleeding, unintentional weight loss or constipation. Abdominal discomfort during bowel movement may signify the presence of a palpable mass.

Unverified Answer

What are common treatments for colorectal cancer?

Add answer

Many colorectal cancer therapies are used. Common strategies include medical treatment, with surgery and/or chemotherapy, and minimally invasive surgical options. Chemotherapy may be used alone or in combination with a variety of surgical methods.

Unverified Answer

What is colorectal cancer?

Add answer

Colorectal cancer is a very common malignancy that threatens one person's life by affecting the anus, bowel or rectum, and sometimes other sites, in the United States. theme:

question: Does e-FITL stimulate proliferation of human colon cancer cells via the PI3K/AKT/mTOR signaling pathway? answer: Our experimental data demonstrate that efitl stimulates the proliferation of colon cancer cells via the PI3K/AKT/mTOR signaling pathway.

Unverified Answer

What are the latest developments in mrtx849 for therapeutic use?

Add answer

MRTX849 may act as an effective combination of a checkpoint inhibitor and a conventional cytostatic agent for therapy of cancer, especially those associated with dysfunctional DNA mismatch repair. The combination of MRTX849 and conventional chemotherapy should be a clinically interesting strategy.

Unverified Answer

How does mrtx849 work?

Add answer

In the current study, we found it effectively reduces growth in a non-invasive and very well-tolerated colon adenoma model. The potential benefit of mrtx849 and its therapeutic approach is likely due to a complex network of molecular pathways and events. Mrtx849 inhibits the MAPKs pathway in the colon adenoma model and induces apoptosis. Mrtx849 also regulates the expression of the tumor suppressor gene RBPJ. RBPJ is a key antagonist of the Wnt signaling pathway, which is activated oncogenic in colon cancer. We found that mrtx849 reduces the cell proliferation/growth of tumor cells in vivo and in vitro.

Unverified Answer

Does mrtx849 improve quality of life for those with colorectal cancer?

Add answer

This is the first large study to show that a treatment with the mrtx849 has a positive effect on QoL for those with colorectal cancer. Recent findings support that mrtx849 has a potential in the adjuvant treatment of colorectal cancer patients.

Unverified Answer

How serious can colorectal cancer be?

Add answer

The seriousness of colorectal cancer depends on the stage of the disease. Larger tumors in the right hemisphere of the bowel are associated with a higher risk of peritoneal involvement. Tumors of any stage in the left colon are associated with a higher risk of peritoneal involvement.

Unverified Answer

What does mrtx849 usually treat?

Add answer

Mrtx849 appears to work most vigorously in treating the advanced stage colon cancer, where it produces over 60% of its effects. In the other stages the response usually fails to match many of the other conventional chemotherapy agents. A multi-center, randomized trial with a significant comparison group and adequate power is urgently needed. In addition, a randomized, phase III trial that addresses important safety concerns, such as progression-free survival, can be done with mrtx849. In March of 2019, Regeneron announced the completion of four phase III clinical trials of their MRTX849 drug. These trials demonstrated the drug’s ability to confer complete tumor regression in advanced stage colon cancer.

Unverified Answer

What is the primary cause of colorectal cancer?

Add answer

Risk factors for colorectal cancer remain undefined and probably numerous. The use of risk factors in the primary prevention efforts, especially in light of the uncertainties regarding their interactions (association and causation), is obviously questionable.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Colorectal Cancer by sharing your contact details with the study coordinator.